Abstract
The standard treatment for advanced gastro-oesophageal cancer in the UK is epirubicin, cisplatin and continuous infusion 5-fluoruracil by an indwelling central venous catheter (ECF), which has significant morbidity. Raltitrexed (tomudex), a specific inhibitor of thymidylate synthase with a long plasma terminal half-life (50–100 h) has activity in gastro-intestinal tract malignancy. To reduce the Hickman line-associated morbidity of ECF; we have conducted a dose-finding study of tomudex combined with epirubicin and cisplatin. Twenty-four patients (22 males, two female), median age 63 years (range 21–75), ECOG performance status ≤ 2 with histologically proven, unresectable or metastatic gastric (14 patients), gastro-oesophageal junction (nine patients) or oesophageal (one patient) adenocarcinoma received treatment with 3-weekly cisplatin 60 mg m–2, epirubicin 50 mg m–2 and tomudex at doses of 2 mg m–2, 2.5 mg m–2 or 3 mg m–2 in successive cohorts. Six patients were treated per dose level with no intra-patient dose escalation. Dose escalation occurred after six patients had completed at least one cycle of chemotherapy at the previous dose level. After defining the maximum tolerated dose a further six patients were treated at the preceding dose level to assess toxicity at the proposed phase II dose. A total of 102 cycles (50% completed 6 cycles) were administered. The dose-limiting toxicities are neutropenia and diarrhoea occurring in 2/6 patients at the 3 mg m–2 dose level. Of those patients evaluable for response, there were eight partial and one complete response (overall response rate 38%). The median survival was 9.9 months. ECT is an active regimen in oesophagogastric adenocarcinoma. The recommended dose of tomudex for further study in combination with epirubicin and cisplatin is 2.5 mg m–2.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allum WH, Powell DJ, McConkey CC and Fielding JW (1989) Gastric cancer: a 25-year review. Br J Surg 76: 535–540
Bajetta E, Di Bartolomeo M, de Braud F, Bozzetti F, Bochicchio AM, Comella P, Fagnani D, Farina G, Ferroni C and Franchi R (1994) Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. Eur J Cancer 30A: 596–600
Bajetta E, Di Bartolomeo M, Carnaghi C, Buzzoni R, Mariani L, Gebbia V, Comella G, Pinotti G, Ianniello G, Schieppati G, Bochicchio AM and Maiorino L (1998) FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. Br J Cancer 77: 1149–1154
Beale P, Judson I, Hanwell J, Berry C, Aherne W, Hickish T, Martin P and Walker M (1998) Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol 42: 71–76
Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H and Johnston PG (1998) Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 4: 1469–1474
Cervantes A, Villar-Grimalt A, Abad A, Anton-Torres A, Belon J, Dorta J, Tres A, Camps C, Fonseca E and Massuti B (1993) 5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol 4: 753–757
Cheng AL, Yeh KH, Lin JT, Hsu C and Liu MY (1998) Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)-a very effective regimen with good patients’ compliance for advanced gastric cancer. Anticancer Res 18: 1267–1272
Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT and Judson IR (1996) Phase I trial of ZD 1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumours. J Clin Oncol 14: 1495–1503
Cunningham D (1998) Mature results from three large controlled studies with raltitrexed (‘Tomudex’). Br J Cancer 77: 15–21
Elliott TE, Moertel CG, Wieand HS, Hahn RG, Gerstner JB, Tschetter LK and Mailliard JA (1990) A phase II study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer. Cancer 65: 1491–1494
Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N and Ford H (1994) A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5: 609–616
Fliser D, Bischoff I, Hanses A, Block S, Joest M, Ritz E and Mutschler E (1999) Renal handling of drugs in the elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharm 55: 205–211
Gore ME, Earl HM, Cassidy J, Tattersall M, Mansi J, Seymour L and Azab M (1995) A phase II study of Tomudex in relapsed epithelial ovarian cancer. Ann Oncol 6: 724–725
Highley MS, Parnis FX, Trotter GA, Houston SJ, Penson RT, Harper PG and Mason RC Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma. Br J Surg 81: 1763–1765
Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A and Boyle FT (1995) Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD 1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914–924
Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res 55: 1407–1412
Kelland LR, Kimbell R, Hardcastle A, Aherne GW and Jackman AL (1995) Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur J Cancer 31A: 981–986
Kondo K, Murase M, Kodera Y, Akiyama S, Ito K, Yokoyama Y, Takagi H and Shirasaka T (1996) Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology 53: 64–67
Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, Esteban E, Gracia JM, Buesa JM and Fernandez OA (1991) Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 2: 751–754
Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J and Leichman L (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. J Clin Oncol 14: 176–182
Meropol NJ, Pazdur R, Vincent M, Willson JK, Kelsen DP and Douglass HO Jr. (1996) Phase II study of ZD 1694 in patients with advanced gastric cancer. Am J Clin Oncol 19: 628–630
Metzger R, Leichmann CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B and Leichman L (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving compbination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309–316
Pazdur R, Meropol NJ, Casper ES, Fuchs C, Douglass HO Jr, Vincent M and Abbruzzese JL (1996) Phase II trial of ZD 1694 (Tomudex) in patients with advanced pancreatic cancer. Investigat New Drugs 13: 355–358
Rigg A, Cunningham D, Gore M, Hill M, O’Brien M, Nicolson M, Chang J, Watson M, Norman A, Hill A, Oates J, Moore H and Ross P (1997) A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Br J Cancer 75: 101–105
Smith I, Jones A, Spielmann M, Namer M, Green MD, Bonneterre J, Wander HE, Hatschek T, Wilking N, Zalcberg J, Spiers J and Seymour L (1996) A phase II study in advanced breast cancer: ZD 1694 (‘Tomudex’) a novel direct and specific thymidylate synthase inhibitor. Br J Cancer 74: 479–481
Sparano JA, Schwartz EL, Salva KM, Pizzillo MF, Wadler S and Wiernik PH (1990) Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. Am J Clin Oncol 13: 374–378
Taal BG, Teller FG, ten Bokkel Huinink WW, Boot H, Beijnen JH and Dubbelman R (1994) Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol 5: 90–92
Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O’Brien M, Iveson T, Watson M, Underhill C, Wardley A and Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15: 261–267
Yeh KH, Shunm CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC and Cheng AL (1998) High expression of thymidylate synthase is associated with drug resistance of gastric carcinoma to high dose 5-fluorouracil based chemotherapy. Cancer 82: 1626–1631
Zaniboni A, Barni S, Labianca R, Marini G, Pancera G, Giaccon G, Piazza E, Signaroldi A, Legnani W and Luporini G (1995) Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer 76: 1694–1699
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Eatock, M., Anthony, D., El-Abassi, M. et al. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma. Br J Cancer 82, 1925–1931 (2000). https://doi.org/10.1054/bjoc.2000.1165
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1165